Transgene - Four Clinical Oncology Assets (Sponsored Reseasrch, TP EUR 3.20, 12 pgs)
With BT-001 advancing into phase I trials, Transgene now has four oncology assets in clinical development and multiple important catalysts in the coming 12 months. TG4001 has started phase II, TG6002 reported first positive human data in April with a further readout in Q4 and most importantly, TG4050 is expected to report an immunological readout in Q4 which could demonstrate proof-of-concept for the technology. Following a €34m raise in June, the company also has financial runway to Q423. Our SOTP values the company at €3.20/share.For access to the full note and our initiation, please contact Naresh Chouhan ( )
Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.